Treatsma website reaches national news in Bhutan

Treatsma website reaches national news in Bhutan.

Away from TreatSMA our volunteers have been busy trying to raise awareness in countries where SMA has never been heard off.

Supporting Palden the second only diagnosed child in Bhutan, our volunteers have been working closely with Paldens mother Ugyen in starting an advocacy group and campaigning for access to treatment and equipment.

With the help of Namgay a fantastic Bhutan national journalist, Palden and her mother reached the biggest ever signed petition in Bhutan directed to Roche to supply treatment to Palden, not to mention introducing the Bhutan population that could potentially have 17,500 carriers to spinal muscular atrophy.

You can read the full press article here.

 

You can follow SMA Bhutan here.


 

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more